title: Radiotherapy of pituitary adenomas: state of the art.
abstract: Pituitary adenomas represent approximately 12% of intracranial tumors. They are defined as tumors that are functional or nonfunctional and invasive or noninvasive. Therapeutic strategies rely on surgery, medical treatment, and radiotherapy depending on histology. Neither the role of external radiotherapy nor the technique to be used are firmly established. Nonfunctioning adenomas must be operated on to relieve the compression. Prolactin-secreting adenomas are first treated with dopamine agonists, and GH-secreting adenomas are first treated by surgery if excising the complete tumor is possible; otherwise medical treatment is started. The first-line treatment of ACTH-secreting adenomas is surgery; however, in many cases, insufficient control of either secretion or tumoral volume leads to consideration of irradiation. Complications of conventional radiotherapy are well known and fractionated stereotactic radiotherapy appears to be as safe as radiosurgery. The volume to irradiate is still difficult to define, and this parameter can influence the technique chosen for treatment. Because the indications of radiotherapy are still debated, irradiation of pituitary adenomas must be decided by the complete team of endocrinologists, neurosurgeons, radiologists and radiotherapists.
authors.affiliation: Département d'oncologie-radiothérapie, centre Jean-Perrin, 58, rue Montalembert, BP 392, 63011 Clermont-Ferrand cedex 01, France. oligilliot@hotmail.com
authors.forename: O
authors.initials: O
authors.lastname: Gilliot
authors.forename: T
authors.initials: T
authors.lastname: Khalil
authors.forename: B
authors.initials: B
authors.lastname: Irthum
authors.forename: X
authors.initials: X
authors.lastname: Zasadny
authors.forename: P
authors.initials: P
authors.lastname: Verrelle
authors.forename: I
authors.initials: I
authors.lastname: Tauveron
authors.forename: D
authors.initials: D
authors.lastname: Pontvert
mesh_terms: D000236:Adenoma / Q000188:drug therapy / Q000401:mortality / Q000532:radiotherapy* / Q000601:surgery; D001932:Brain Neoplasms / Q000453:epidemiology; D003131:Combined Modality Therapy; D005500:Follow-Up Studies; D019382:Human Growth Hormone / Q000378:metabolism; D006801:Humans; D010911:Pituitary Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000532:radiotherapy* / Q000601:surgery; D011388:Prolactin / Q000378:metabolism; D016019:Survival Analysis; D017741:Survivors
chemical_list: D019382:Human Growth Hormone; D011388:Prolactin